Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 22,390

Document Document Title
WO/2023/195544A1
The present invention provides an enzyme that phosphorylates the 2'-hydroxyl group of an RNA, etc.  
WO/2023/196967A1
The invention discloses approaches to reduce expression of a gene in a cell.  
WO/2023/194641A1
Disclosed are antagonists of human micro RNA miR-100, miR-20, miR-222, miR-181 and miR-92 and uses of same. The invention provides inhibitors of human micro-RNA miR-100, miR-20a, miR-222, miR-181c and miR-92a, which are repressors of the...  
WO/2023/196853A1
The present invention relates to compositions and methods for preventing disease, delaying the progression of disease, and/or treating patients with one or more 5' mutations of the dystrophin (DMD) gene. The invention provides recombinan...  
WO/2023/195527A1
The purpose of the present invention is to increase the amount of oligo-nucleic acid transported into a cytoplasm by bringing about an efficient interaction of a cell uptake promoter with a target cell. An oligo-nucleic acid nanoparticle...  
WO/2023/195432A1
By providing are a refractory neurological disorder treatment composition, and a method for producing the same, it is possible to treat amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The refractory neurological disorder tre...  
WO/2023/192530A1
Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal neurodegenerative disease in humans. The underlying hallmarks of the disease involve lipid peroxidation (LPO) of polyunsaturated fatty acids (PUFAs) in the motor neurons. Ce...  
WO/2023/187022A1
The invention provides an anti-myostatin antibody for use in the treatment, prevention, delaying progression and/or amelioration of Facioscapulohumeral muscular dystrophy (FSHD).  
WO/2023/192361A1
Methods of treating a subject for fibromyalgia are provided. Aspects of the methods include administering to the subject a tropane CCR5/CCL5 interaction inhibitor, either alone or in combination with a statin, to treat the subject for fi...  
WO/2023/190935A1
The present invention aims to provide a novel therapeutic approach to human myopathy (particularly titin-based myopathy). The present invention provides a polynucleotide comprising the following base sequences: (a) a base sequence encodi...  
WO/2023/190316A1
The present invention provides a preventive or therapeutic agent for neurodegenerative disease, the agent containing an agent for suppressing KLHL32 gene expression. The present invention also provides a screening method for a preventive...  
WO/2023/191077A1
The present invention addresses the problem of stratifying the frailty progression evaluation of a subject. This method for assisting the stratification of the evaluation of frailty progression level of a subject, the method comprising...  
WO/2023/186016A1
The present invention provides a botulinum toxin protein composition, mainly comprising botulinum toxin protein, a saccharide, a salt, and human serum albumin. The botulinum toxin protein composition of the present invention features goo...  
WO/2023/189485A1
The present invention provides a method for evaluating the quality of mesenchymal stem cells, said method including a step for evaluating the cells on the basis of the measured consumption amounts of pyruvic acid, cystine and serine in t...  
WO/2023/190897A1
The present invention provides a discovery of a new compound that can be used as a muscle relaxant. Specifically, the present invention provides a compound represented by general formula (I) or a pharmacologically acceptable salt thereof...  
WO/2023/190532A1
A gaseous pharmaceutical composition for treating rhabdomyolysis, said composition containing nitric oxide gas.  
WO/2023/185017A1
Provided is modified RNF112 or an exosome delivery system containing same. Further provided is a fusion RNA or a fusion DNA, wherein the fusion RNA or the fusion DNA contains a coding sequence of the modified RNF112 protein, which coding...  
WO/2023/190809A1
The present invention addresses the problem of providing: a new food component that inhibits production of cortisol; and a composition containing the food component. The present invention provides a composition that is for inhibiting p...  
WO/2023/190797A1
Provided are technique for improving muscle quality and technique related thereto. The present invention improves muscle quality by using a choline compound such as sn-Glycero-3-phosphocholine (αGPC) or citicoline.  
WO/2023/185261A1
Provided is a DNA delivery system using an exosome as a vector. The DNA delivery system comprises a DNA packaging system and a targeted delivery vector. The DNA packaging system can introduce a DNA sequence with a modified RNF112 gene in...  
WO/2023/182342A1
The present invention provides a means for enhancing skeletal muscles. Specifically, spermidine or a pharmaceutically acceptable salt thereof is intramuscularly administered as an active ingredient.  
WO/2023/182656A1
The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases, the pharmaceutical composition comprising Levodropropizine as an active ingredient. The pharmaceutical composition can effectively ...  
WO/2023/182761A1
The present application relates to an aldehyde-substituted hyaluronic acid derivative modified with a gallol group, and a use thereof. According to one embodiment of the present invention, the aldehyde-substituted hyaluronic acid derivat...  
WO/2023/180245A1
According to the WHO, the population aged 60 and over will have doubled by 2050. Unfortunately, aging comes along with an explosion of aging-associated disorders, such as metabolic and cardiovascular diseases, bone and muscle weakening, ...  
WO/2023/183926A1
The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or human...  
WO/2023/182657A1
The present invention relates to an anti-Fetuin-B antibody and a composition comprising the corresponding antibody as an active ingredient for the prevention, treatment, or alleviation of muscle diseases, wherein the antibody and composi...  
WO/2023/183860A1
The invention relates to myotropic extracellular vesicle compositions comprising a muscle-targeting membrane protein and optionally one or more therapeutic agents. The invention further relates to methods of using the myotropic extracell...  
WO/2023/180956A1
Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the treatment and prevention of spasticity in humans.  
WO/2023/180813A1
A composition, a compound, and a method are provided for improving skeletal muscle endurance, treating muscle atrophy or dystrophy, or preventing muscle atrophy or dystrophy in a subject in need thereof. Such a composition includes an ef...  
WO/2023/182288A1
The present invention provides a drug for treating or preventing Charcot-Marie-Tooth disease, said drug comprising a compound represented by formula (I) (in formula (I), the symbols are as defined in the attached description) or formula ...  
WO/2023/175010A1
The invention relates to the use of bazedoxifene as representing third-generation SERM, namely compounds comprising a 2-phenylindole group, for increasing muscle survival, in particular in the treatment of dysferlinopathies.  
WO/2023/177283A1
The invention provides a follistatin in combination with a bisphosphonate for use in a method of counteracting a condition of bone loss and/or muscle loss in a subject.  
WO/2023/178053A1
Disclosed are nucleic acids comprising or consisting of the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO:2, or variants thereof. Also disclosed are recombinant expression cassettes comprising a promoter comprising SEQ ID NO: 1 or S...  
WO/2023/177675A1
Embodiments of the application provide methods and systems for the relaxation of target tissues (10) of mammals (1) using a treatment (2) having a natural substance (3). A natural substance may be a plant-based or even an algae-based sub...  
WO/2023/177234A1
The present invention, which has been completed after discovering the skeletal muscle mitochondrial function improvement, muscle atrophy inhibition, and muscle synthesis promotion effects of an extract of Aster glehni Fr. Schm, provides ...  
WO/2023/178230A1
Novel antisense oligonucleotide conjugates that cause skipping of an exon in the human dystrophin gene and their use in a method of treating muscular dystrophy in a patient suffering from Duchenne muscular dystrophy (DMD) are described.  
WO/2023/174039A1
Disclosed herein are anti-MASP-2 antibodies and antigen-binding fragments, polynucleotides encoding the antibodies and antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and antigen-binding fragments. Us...  
WO/2023/177128A1
The present invention relates to a composition comprising an Alox5 inhibitor for preventing or treating sarcopenia, and comprises a material that targets Alox5 so as to inhibit the expression or activation thereof, and thus improves musc...  
WO/2023/174463A1
The present invention provides a method of preparation of a biological therapeutic product based on perinatal tissue, characterized in that the method includes the steps of: a) cleaning of the starting perinatal tissue and optionally its...  
WO/2023/171806A1
The present invention provides a novel therapeutic or prophylactic agent that can treat or prevent diseases associated with mitochondrial dysfunctions. The present invention provides a therapeutic or prophylactic agent for diseases assoc...  
WO/2023/172115A1
The present invention relates to a composition and method for increasing deletion efficiency of nucleic acid segments in a target gene by modulation of non-homologous end joining (NHEJ) repair pathway. Specifically, the present invention...  
WO/2023/171587A1
[Problem] To provide a chemically-modified siRNA that has improved stability against RNase enzymes and selectively inhibits the expression of P525L mutant FUS which is a causative gene of ALS. [Solution] Provided is a chemically-modified...  
WO/2023/171106A1
An agent for suppressing aggregation of TDP-43, the agent comprising at least one selected from the group consisting of cycloserine, terizidone, and salts thereof.  
WO/2023/171820A1
In the present description, there are provided; a nucleic acid having a carrier peptide linked thereto, or a pharmaceutically acceptable salt of the nucleic acid, or a hydrate of the nucleic acid or the pharmaceutically acceptable salt; ...  
WO/2023/172116A1
The present invention relates to a gene editing system for treating Duchenne muscular dystrophy, and a method for treating the disease using same. An aspect of the present invention has the effects of making it possible to package the ge...  
WO/2023/167094A1
Disclosed are a 5'-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is a compound represented by formula (I) or a salt thereof. The nucleoside of the present invention has suitable duplex-formi...  
WO/2023/165925A1
The present invention relates to a modified recombinant agrin protein or a fragment thereof and a recombinant chimeric laminin-nidogen protein or a fragment thereof, to nucleic acid sequences encoding these proteins, to vectors comprisin...  
WO/2023/168280A1
Provided herein are methods for treating at least one symptom of ALS in a subject who has received a first dosage of a substrate of a CYP or a transporter, the method including administering to the subject a composition comprising a bile...  
WO/2023/168458A1
SnRNA systems comprising engineered stem loops are disclosed herein.  
WO/2023/167033A1
Provided is a prorenin receptor peptide having enhanced ability to induce an antibody against a prorenin receptor. The prorenin receptor peptide of the present disclosure includes the following polypeptide (P1), (P2) or (P3): (P1) a po...  

Matches 151 - 200 out of 22,390